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THE major risks of islet transplantation described in the past, portal hypertension, 1 portal vein thrombosis 
and hepatic infarction,2 and coagu1opathy3 have been 
solved by the current methods of purification of islet 
preparations that allow for an infusion of low volume 
(usually < 2 mL) of highly purified cells. Since patients 
who receive islet grafts are immunosuppressed, infection 
is always of concern. Microbiologic quality control sam-
ples have been recommended as a mandatory part of any 
clinical islet cell program to assess the infectious risk of 
islet cell transplant since contamination of transport solu-
tion is not uncommon and contamination of reagents can 
occur.4 .5 We have performed quality control microbiologic 
surveillance during human islet isolations from pancreata 
considered for possible clinical transplantation and found 
that. while the transport solution is frequently contam-
inated, the final islet preparations were sterile even when 
obtained from a pancreas with an infected pseudocyst. 
METHODS 
Between January 10, 1990 and the time of this repon, 26 patients 
underwent islet cell transplantation with one or more purified islet 
cell preparations for indications of extensive cancer resection 
(cluster with liver transplantation),6 autograft, or type I diabetes 
with simultaneous liver or kidney transplantation. 
Pancreas Procurement 
The pancreata were obtained from multiorgan donors. 7 In situ 
perfusion of the abdominal aom was with 1500 to 2000 mL of 
University of Wisconsin solution (UWS). 
An additional 500 to 1000 mL of UWS was infused directly into 
the liver via the pona1 vein. that was encircled below the catheter 
tip to prevent retrograde leakage. Venous hypenension of the 
pancreas was avoided by venting the pona1 and/or splenic vein. 
The specimens were immersed in UWS and packed on ice. 
Isolation and Purification of Human Islets 
Human islets were obtained by a modificationS of the automated 
procedure.9 The islets were purified on discontinuous gradients of 
Eurocollins Ficoll (Ficoll DL-400, Sigma. 8t Louis. Mo) at den-
sities of 1.108, 1.096, and 1.037. The gradients were prepared 
fresh for each human isolation. The cells were purified by centrif-
ugation through the gradients on a Cobe 2991 cell separator (Cobe, 
Lakewood, Colo).lo.11 
Gradient Preparation 
All reagents used in the isolations reponed herein were prepared 
fresh using aseptic technique, under a class II laminar flow hood 
(Nuaire, model 425-600, Plymouth, Minn). Routine surgical asep-
sis was used in the laboratory that was not a class 100 clean room. 
Stock ficoll solution was completed then filtered under the hood 
using a 0.2 micron filter (Millipore, Milipak 200, Bedford, Mass). 
Afterfiitering, the final Ficoll stock solution was autoclaved for 13 
minutes. 
Quality Control Samples 
Routine samples were taken from the transpon UWS solution, the 
stock Ficoll solution used to prepare gradients, and the final islet 
preparation. 
In the case of the autografts, a small section of pancreas was 
also cultured. 
The sterile container with the pancreas in UW8 was transferred 
to the hood and opened. The pancreas was removed and placed 
into a stainless steel pan on ice with sterile Hank's solution for 
funher processing. Approximately 10 mL of UWS was removed 
from the transfer container with a sterile syringe and 5 mL were 
injected under sterile conditions into culture vials of soybean-
casein digest broth (anaerobic) and tryptic soy broth (aerobic) 
Bactec (Beckton Dickinson Diagnostic Instrument Systems, 
Townson, Md). Five milliliters of the stock ficoll used in the 
isolation were processed similarly. After the purification step was 
completed, 0.1 mL of the final islet preparation was resuspended 
in 10 mL of the supernatant from the last wash and 5 mL of this 
solution were injected into the aerobic and anaerobic culture 
bottles as described above. The aerobic culture vials have resins 
that increase the likelihood of culturing organisms even in the 
presence of antibiotics used during the isolation. All samples were 
processed for growth of aerobic, anaerobic, and fungal organisms, 
and were incubated for 5 days. If the vials showed any growth 
during this time period, they were examined by gram stain and 
were processed funher for identification and sensitivity studies. 
RESULTS 
The UWS was contaminated with microbes in 8 of 26 
isolations (31%). Patients received antibiotic coverage for 
bacterial contaminants found in UWS until final results of 
islet preparations were known. The organisms culbJred 
from UWS included aerobic, anaerobic, and fungal organ-
isms. The most common organism isolated was coagulase-
negative Staphylococci. There was no instance of contam-
ination of stock Ficoll solutions used in clinical 
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transplants. The final islet preparations were all free of 
contamination. This included one isolation for autotrans-
plant in which a pseudocyst from the native pancreas 
cultured positive for Pseudomonas maltophiLia, but after 
being processed using standard techniques. the final islet 
preparation showed no growth of the organism. This 
patient received a full course of antibiotics for the infected 
pseudocyst independent of these results. No patients had a 
systemic infection related to an islet cell graft. 
DISCUSSION 
The frequency of contamination of UWS for transport of 
pancreata are compatible with data obtained by other 
investigators who reported that between 25% and 68% of 
transport solutions processed per year were contaminated 
with one or several organisms. 12 Ficoll stock solution has 
been a significant source of addition of microbial contam-
inants in the past. The sterility of the current samples may 
'"cfiect the introduction of filtering the prepared stock 
solution through the Millipore Millipak prior to auto-
claving. 
We have recently moved our basic and clinical facilities 
into a class 100 laminar air fiow clean room for human islet 
isolation. This is suggested to decrease introduced mi-
crobes considerablyl3; however the data reported herein 
attest to the safety of processing cells using a standard 
clean room and aseptic operating room techniques if such 
a facility is not available. Quality control microbial surveil-
lance of transport solutions. reagents, and the final islet 
preparations used for clinical transplantation must con-
2799 
tinue to be part of the assessment of materials used for 
clinical transplantation. 
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